Business Insider write, “The Asia-Pacific medicinal cannabis market has been tipped to heat-up by the two companies involved in the launch of a new Australia-based marijuana cultivation business. ”
But here at CLR we note their article fails to to mention the impossibility of getting medical cannabis prescriptions in Australia, the neanderthal approach to cannabis regulation by most federal and state politicians in the country, the out of control black market for cannabis in Australia, never mind the bureaucracy involved for those who actually want to create positive outcomes from the “regulated” market in Australia.
The fantasy that Australia has a cannabis sector is led in the main by a cabal of “corporate” industry players and their ‘relationship’ with the markets and press is at, very best, a misnomer where currently very few people will make money out of medical cannabis exported to other jurisdictions.
Here’s what Business insider have to say about the latest deals that need to be sold up.
Aussie startup Greenfield MC — which was launched in 2018 as an importer and distributor of medicinal cannabis — will now become a grower, under the terms of a new deal with US-Canadian company Emerald Plants Health Source (EPHS).
The two companies will create a joint venture business, Greenfield MC Cultivation, which will develop a cannabis growing operation in Australia for export across the Asia-Pacific market, Business Insider Australia can reveal. There are 20 organisations listed on the Australian Office of Drug Control’s website as having secured a licence to cultivate medicinal cannabis, though it is unclear how many have actually started producing.
EPHS — which is licensed to grow and distribute cannabis in Canada and listed on the New York-based OTC stock exchange — is anticipating the Asia-Pacific medicinal cannabis market will become the world’s largest as demand for cannabis-based treatment grows.
“Australia’s reputation for best agricultural practices, crop safety management systems and robust quality control will make Australian-grown cannabis the envy of the global market and provide patients with confidence in this new form of medical treatment,” said Kevin Smith, vice president for strategy and business development at EPHS.
“For those very reasons, we see Australia as the gateway to Asia, which it already is in various agricultural and pharmaceutical product categories.”
